Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
Deferiprone is only a second-line option for the treatment of iron overload. The convenience of oral intake does not compensate for the lack of evidence concerning effects on morbidity and/or mortality. In contrast, deferoxamine, an injectable product, has proven clinical efficacy. However, seven years after initial marketing of deferiprone, its adverse effects (mainly neutropenia and agranulocytosis) are now better documented.
D000284:Administration, Oral; D005602:France; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy*; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013789:Thalassemia / Q000150:complications; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D011728:Pyridones